Literature DB >> 21352803

MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer.

Jun Hao1, Shuyu Zhang, Yingqi Zhou, Cong Liu, Xiangui Hu, Chenghao Shao.   

Abstract

MicroRNAs (miRNAs) have emerged as important regulators in the development of pancreatic cancer and may be a valuable therapeutic application. DPC4/Smad4 is a critical tumor suppressor involved in the progression of pancreatic cancer, but few studies have been conducted to determine its relationship with miRNAs. In this study, we identify miR-421 as a potential regulator of DPC4/Smad4. We find that in human clinical specimens of pancreatic cancer miR-421 is aberrantly upregulated while DPC4/Smad4 is strongly repressed, and their levels of expression are inversely correlated. Moreover, ectopic expression of miR-421 significantly decreases DPC4/Smad4 protein level in pancreatic cancer cell lines and simultaneously promotes cell proliferation and colony formation in vitro. Our findings identify miR-421 as a potent regulator of DPC4/Smad4, which may provide a novel therapeutic strategy for treatment of DPC4/Smad4-driven pancreatic cancer.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21352803     DOI: 10.1016/j.bbrc.2011.02.086

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  44 in total

1.  E2F1-dependent miR-421 regulates mitochondrial fragmentation and myocardial infarction by targeting Pink1.

Authors:  Kun Wang; Lu-Yu Zhou; Jian-Xun Wang; Yin Wang; Teng Sun; Bing Zhao; Yong-Jie Yang; Tao An; Bo Long; Na Li; Cui-Yun Liu; Ying Gong; Jin-Ning Gao; Yan-Han Dong; Jian Zhang; Pei-Feng Li
Journal:  Nat Commun       Date:  2015-07-17       Impact factor: 14.919

2.  Integrative Analysis of miRNA and inflammatory gene expression after acute particulate matter exposure.

Authors:  Valeria Motta; Laura Angelici; Francesco Nordio; Valentina Bollati; Serena Fossati; Fabio Frascati; Valentina Tinaglia; Pier Alberto Bertazzi; Cristina Battaglia; Andrea A Baccarelli
Journal:  Toxicol Sci       Date:  2013-01-28       Impact factor: 4.849

3.  miR-421 is a diagnostic and prognostic marker in patients with osteosarcoma.

Authors:  Shuguang Zhou; Bing Wang; Jun Hu; Yucheng Zhou; Mengzhen Jiang; Mingyu Wu; Liming Qin; Xuming Yang
Journal:  Tumour Biol       Date:  2016-01-13

4.  MiR-421 Is Overexpressed and Promotes Cell Proliferation in Non-Small Cell Lung Cancer.

Authors:  Xing Li; Shao-Hua Chen; Jin-Wu Zeng
Journal:  Med Princ Pract       Date:  2019-09-02       Impact factor: 1.927

Review 5.  miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.

Authors:  Anteneh A Tesfaye; Asfar S Azmi; Philip A Philip
Journal:  Am J Pathol       Date:  2019-01       Impact factor: 4.307

Review 6.  Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.

Authors:  Satyanarayana Rachagani; Muzafar A Macha; Nicholas Heimann; Parthasarathy Seshacharyulu; Dhanya Haridas; Seema Chugh; Surinder K Batra
Journal:  Adv Drug Deliv Rev       Date:  2014-10-23       Impact factor: 15.470

7.  MiR-421 inhibits the malignant phenotype in glioma by directly targeting MEF2D.

Authors:  Liang Liu; Sitong Cui; Rui Zhang; Yan Shi; Liangsheng Luo
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

Review 8.  Smoking and microRNA dysregulation: a cancerous combination.

Authors:  Navneet Momi; Sukhwinder Kaur; Satyanarayana Rachagani; Apar K Ganti; Surinder K Batra
Journal:  Trends Mol Med       Date:  2013-11-13       Impact factor: 11.951

9.  Gastric juice microRNA-421 is a new biomarker for screening gastric cancer.

Authors:  Xinjun Zhang; Long Cui; Guoliang Ye; Tuo Zheng; Haojun Song; Tian Xia; Xiuchong Yu; Bingxiu Xiao; Yanping Le; Junming Guo
Journal:  Tumour Biol       Date:  2012-08-29

Review 10.  microRNAs in liver disease: from diagnostics to therapeutics.

Authors:  Kenji Takahashi; Irene Yan; Hui-Ju Wen; Tushar Patel
Journal:  Clin Biochem       Date:  2013-02-07       Impact factor: 3.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.